



Onyx Dkt No. 1046.ORD
USSN: 09/410,462
PATENT

CERTIFICATE OF FIRST CLASS MAILING (37 CFR 1.8)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the following date:

17 Jan 2006
Date

Gary R Fabrein
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Williams, A., et al.	Confirmation No. 6889
Serial No.: 09/410,462	Art Unit: 1635
Filing Date: 1 October 1999	Examiner: J.E. Angell
Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS USING ADENOVIRAL MUTANTS	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing are an Information Disclosure Statement, a modified Form PTO-1449, and a copy of one non-U.S. Patent publication.

The Examiner is respectfully requested to make this information of official record in the application.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

It is believed that no fee is due for this Information Disclosure Statement, which contains the publicly-available, published GenBank sequence for the wild-type type 5 adenovirus genome sequence discussed in the specification on page 8, line 29.

Onyx Dkt No. 1046.ORD
USSN: 09/410,462
PATENT

However, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 15-0615 (reference number: ONYX1046.ORD). However, this is not authorization to pay the Issue Fee.


Respectfully submitted,

Dated: 17 Jan 2006

By: Gary R. Fabian
Gary R. Fabian
Agent for Applicants
Registration No. 33,875

ONYX Pharmaceuticals, Inc.
2100 Powell Street
Emeryville, CA 94608
Phone: (510) 597-6502
Facsimile: (510) 597-6610

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450



FORM PTO-1449 (Modified)
 LIST OF PATENTS AND PUBLICATIONS
 FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
 (Use several sheets if necessary)
 Sheet 1 of 1

In the Application of: Williams, A., et al.

Confirmation No.: 6889

Serial No.: 09/410,462

Art Unit: 1635

Filed: 1 October 1999

Examiner: J.E. Angell

Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS USING ADENOVIRAL MUTANTS

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
	AC-01						

FOREIGN PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES NO
	BC-01						

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
	CC-01	NCBI Nucleotide Sequence, GenBank Accession No. M73260, VRL: 08-APR-1996, The Sequence of the Genome of Adenovirus Type 5; Authors: Chroboczek, J., et al.

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.